Literature DB >> 25108566

Adiponectin stimulates Rho-mediated actin cytoskeleton remodeling and glucose uptake via APPL1 in primary cardiomyocytes.

Rengasamy Palanivel1, Riya Ganguly1, Subat Turdi1, Aimin Xu2, Gary Sweeney3.   

Abstract

OBJECTIVE: Adiponectin is known to confer its cardioprotective effects in obesity and type 2 diabetes, mainly by regulating glucose and fatty acid metabolism in cardiomyocytes. Dynamic actin cytoskeleton remodeling is involved in regulation of multiple biological functions, including glucose uptake. Here we investigated in neonatal cardiomyocytes whether adiponectin induced actin cytoskeleton remodeling and if this played a role in adiponectin-stimulated glucose uptake. MATERIALS/
METHODS: Primary cardiomyocytes were treated with full-length and globular adiponectin (fAd and gAd, respectively).
RESULTS: Both fAd and gAd increased RhoA activity, phosphorylation of the Rho/ROCK signaling target cofilin and actin polymerization to form filamentous actin as determined by rhodamine-phallodin immunofluorescence and quantitative analysis of filamentous to globular actin ratio. Scanning electron microscopy also demonstrated structural remodeling. Adiponectin stimulated glucose uptake, was significantly abrogated in the presence of inhibitors of actin cytoskeleton remodeling (cytochalasin D) and Rho/ROCK signaling (C3 transferase, Y27632). We showed that adiponectin increased colocalization of actin and APPL1 and that actin remodeling, phosphorylation of AMPK, p38MAPK and cofilin, glucose uptake and oxidation were all attenuated after siRNA-mediated knockdown of APPL1.
CONCLUSION: We show that adiponectin mediates Rho/ROCK-dependent actin cytoskeleton remodeling to increase glucose uptake and metabolism via APPL1 signaling.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APPL1; Actin cytoskeleton; Adiponectin; Cardiomyocyte; Glucose uptake

Mesh:

Substances:

Year:  2014        PMID: 25108566     DOI: 10.1016/j.metabol.2014.07.005

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  14 in total

Review 1.  Electrical and mechanical stimulation of cardiac cells and tissue constructs.

Authors:  Whitney L Stoppel; David L Kaplan; Lauren D Black
Journal:  Adv Drug Deliv Rev       Date:  2015-07-30       Impact factor: 15.470

Review 2.  Nutrient sensing and utilization: Getting to the heart of metabolic flexibility.

Authors:  Timothy M Griffin; Kenneth M Humphries; Michael Kinter; Hui-Ying Lim; Luke I Szweda
Journal:  Biochimie       Date:  2015-10-22       Impact factor: 4.079

3.  Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections with Obesity.

Authors:  Carly B Garrison; Kristin J Lastwika; Yuzheng Zhang; Christopher I Li; Paul D Lampe
Journal:  J Proteome Res       Date:  2016-11-14       Impact factor: 4.466

4.  Tracking adiponectin biodistribution via fluorescence molecular tomography indicates increased vascular permeability after streptozotocin-induced diabetes.

Authors:  Nanyoung Yoon; Keith Dadson; Thanh Dang; Teresa Chu; Nina Noskovicova; Boris Hinz; Adeline Raignault; Eric Thorin; Seunggyu Kim; Jessie S Jeon; James Jonkman; Trevor D McKee; Justin Grant; Jeffrey D Peterson; Scott P Kelly; Gary Sweeney
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-07-16       Impact factor: 4.310

5.  Adiponectin is associated with early diabetic kidney disease in adults with type 1 diabetes: A Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study.

Authors:  Petter Bjornstad; Laura Pyle; Gregory L Kinney; Marian Rewers; Richard J Johnson; David M Maahs; Janet K Snell-Bergeon
Journal:  J Diabetes Complications       Date:  2016-06-14       Impact factor: 2.852

6.  Lack of adiponectin and adiponectin receptor 1 contributes to benign prostatic hyperplasia.

Authors:  Shi Fu; Huan Xu; Meng Gu; Chong Liu; Xiang Wan; Yanbo Chen; Qi Chen; Juan Zhou; Zhong Wang
Journal:  Oncotarget       Date:  2017-08-03

7.  Adiponectin deficiency contributes to the development and progression of benign prostatic hyperplasia in obesity.

Authors:  Shi Fu; Huan Xu; Meng Gu; Chong Liu; Qiong Wang; Xiang Wan; Yanbo Chen; Qi Chen; Yubing Peng; Zhikang Cai; Juan Zhou; Zhong Wang
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

Review 8.  Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines.

Authors:  Kyoung-Jin Oh; Da Som Lee; Won Kon Kim; Baek Soo Han; Sang Chul Lee; Kwang-Hee Bae
Journal:  Int J Mol Sci       Date:  2016-12-22       Impact factor: 5.923

Review 9.  Examining the Potential of Developing and Implementing Use of Adiponectin-Targeted Therapeutics for Metabolic and Cardiovascular Diseases.

Authors:  Ying Liu; Vivian Vu; Gary Sweeney
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-11       Impact factor: 5.555

10.  Cardiopulmonary Dysfunction and Adiponectin in Adolescents With Type 2 Diabetes.

Authors:  Petter Bjornstad; Uyen Truong; Jennifer L Dorosz; Melanie Cree-Green; Amy Baumgartner; Gregory Coe; Laura Pyle; Judith G Regensteiner; Jane E B Reusch; Kristen J Nadeau
Journal:  J Am Heart Assoc       Date:  2016-03-18       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.